第一个被批准用于临床的多靶点的靶向抗癌新药——索拉非尼
被引量：1
摘要
索拉非尼临床研究进展
2005年12月美国FDA首先批准索拉非尼作为不能手术切除的晚期肾细胞癌（RCC）的一线治疗药物上市；2007年10月欧洲药品评价局（EMEA）批准索拉非尼用于治疗肝细胞癌（HCC）、2007年11月美国FDA批准索拉非尼作为未能手术切除的肝细胞癌的治疗药物上市。此外，目前世界各地还有近50项应用索拉非尼治疗其他多种癌症的各类临床试验正在进行中。
同被引文献14
-
1Wilhelm SM.BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis[J].Cancer Res,2004,64(19):7099-7109.
-
2Chang YS,Adnane J.Sorafenib(BAY 43-9006) inhibits tumors growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models[J].Cancer Chemother Pharmacol,2007,59(5):561-574.
-
3Liu L,Chen C.Sorafenib blocks the RAF/MEK/ERK pathway,inhibits tumor angiogenesis,and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5[J].Cancer Res,2006,66(24):11851-11858.
-
4Carter CA.Sorafenib is efficacious and tolerated in combination with cytotoxic or cytostatic agents in preclinical models of human non-small cell lung carcinoma[J].Cancer Chemother Pharmacol,2007,59(2):183-195.
-
5Strumberg D,Clark JW,Awada A,et al.Safety,pharmacokinetics,and preliminary antitumor activity of sorafenib:a review of four phase I trials in patients with advanced refractory solid tumors[J].Oncologist,2007,12(4):426-437.
-
6Ratain MJ,Eisen T.Phase Ⅱ Placebo-Controlled Randomized Discontinuation Trial of Sorafenib in Patients With Metastatic Renal Cell Carcinoma[J].J Clin Oncol,2006,24(16):2505-2512.
-
7Escudier B,Eisen T.Sorafenib for Treatment of Renal Cell Carcinoma:Final Efficacy and Safety Results of the Phase Ⅲ Treatment Approaches in Renal Cancer Global Evaluation Trial[J].J Clin Oncol,2009,27(20):3312-3318.
-
8Llovet JM,Ricci S.Sorafenib in advanced hepatocellular carcinoma[J].New Engl J Med,2008,359(4):378-390.
-
9Gatzemeier U,Blumenschein GR Jr,Fossella F,et al.Phase II,m ulticenter,uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory,advanced non-small-cell lung cancer[J].J Clin Oncol,2009,27(26):4274-4280.
-
10Lind JS,Dingemans AC.A Multicenter Phase Ⅱ Study of Erlotinib and Sorafenib in Chemotherapy-Na?ve Patients with Advanced Non-Small Cell Lung Cancer[J].Clin Cancer Res,2010,16(11):3078-3087.
-
1两类抗抑郁药不适用于儿童[J].柳州医学,2006,19(3):134-134.
-
2我国抗癌新药盐酸埃克替尼完成Ⅲ期临床试验[J].中国处方药,2010(9):15-15.
-
3欧洲药品评价局认为两类抗抑郁药不应用于儿童和青少年[J].中国新药与临床杂志,2005,24(8):594-594.
-
4刘建平.中医药治疗不能手术的胰腺癌[J].中西医结合学报,2006,4(4):338-338.
-
5欧洲药品管理局认为两类抗抑郁药不应超适应证用于儿童和青少年[J].中国药物警戒,2005,2(3):186-186. 被引量：2
-
6郑晶心.EMEA公布流感疫苗指南草案[J].国外药讯,2004(4):3-3.
-
7马培奇.国外新近批准主要新药（六十一）[J].中国制药信息,2011,27(12):20-26.
-
8张首国,王林.经一氧化氮途径的靶向抗癌[J].国外医学（药学分册）,2003,30(6):371-371. 被引量：1
-
9杨剑霞.厄洛替尼治疗晚期非小细胞肺癌致皮肤不良反应的观察和护理[J].护理研究（中旬版）,2009,23(5):1286-1287. 被引量：6
-
10王乐民,时骏,崔芳.“文迪雅”安全性等待评价[J].中国社区医师（医学专业）,2007,9(12):59-59.
